Genetic contribution of the leukotriene pathway to coronary artery disease

[1]  S. Hazen,et al.  Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy , 2010, Journal of Lipid Research.

[2]  Yongmei Liu,et al.  Human Lipoxygenase Pathway Gene Variation and Association with Markers of Subclinical Atherosclerosis in the Diabetes Heart Study , 2010, Mediators of inflammation.

[3]  H. Allayee,et al.  Functional analysis of 5-lipoxygenase promoter repeat variants. , 2009, Human molecular genetics.

[4]  Weihong Tang,et al.  Associations of genetic polymorphisms of arachidonate 5-lipoxygenase-activating protein with risk of coronary artery disease in a European-American population. , 2009, Atherosclerosis.

[5]  T. Lumley,et al.  Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. , 2009, Atherosclerosis.

[6]  E. Zintzaras,et al.  Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE gene-disease association review and meta-analysis. , 2009, American journal of epidemiology.

[7]  W. Kraus,et al.  Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis , 2009, Human Genetics.

[8]  I. König,et al.  Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German population. , 2008, Clinical science.

[9]  J. Connelly,et al.  ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. , 2008, Atherosclerosis.

[10]  A. Lusis,et al.  Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction. , 2008, The American journal of clinical nutrition.

[11]  P. Wołkow,et al.  The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[12]  N. Samani,et al.  Arachidonate 5-lipoxygenase (5-LO) promoter genotype and risk of myocardial infarction: a case-control study. , 2008, Atherosclerosis.

[13]  A. Lusis,et al.  Identification of ALOX5 as a gene regulating adiposity and pancreatic function , 2008, Diabetologia.

[14]  T. Meitinger,et al.  Genetic Variation in Members of the Leukotriene Biosynthesis Pathway Confer an Increased Risk of Ischemic Stroke: A Replication Study in Two Independent Populations , 2008, Stroke.

[15]  T. Assimes,et al.  Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease , 2008, Human Genetics.

[16]  E. Topol,et al.  Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. , 2008, JAMA.

[17]  W. Henderson,et al.  Mechanisms of disease: Leukotrienes , 2007 .

[18]  R. Gerszten,et al.  Inhibited Aortic Aneurysm Formation in BLT1-Deficient Mice1 , 2007, The Journal of Immunology.

[19]  E. Coto,et al.  A functional Sp1/Egr1‐tandem repeat polymorphism in the 5‐lipoxygenase gene is not associated with myocardial infarction , 2007, International journal of immunogenetics.

[20]  C. Carlson,et al.  TagSNP evaluation for the association of 42 inflammation loci and vascular disease: evidence of IL6, FGB, ALOX5, NFKBIA, and IL4R loci effects , 2007, Human Genetics.

[21]  A. Kastrati,et al.  No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population , 2007, Genetics in Medicine.

[22]  Suzanne Cheng,et al.  Association Between A Leukotriene C4 Synthase Gene Promoter Polymorphism and Coronary Artery Calcium in Young Women: The Muscatine Study , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[23]  P. Ridker,et al.  Genetic Variants of Arachidonate 5-Lipoxygenase–Activating Protein, and Risk of Incident Myocardial Infarction and Ischemic Stroke: A Nested Case-Control Approach , 2006, Stroke.

[24]  Anders Gabrielsen,et al.  Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Allayee.  Non-conventional genetic risk factors for cardiovascular disease. , 2006, World review of nutrition and dietetics.

[26]  P. Patel,et al.  Nonconventional genetic risk factors for cardiovascular disease , 2006, Current atherosclerosis reports.

[27]  M. Rudling,et al.  Inhibition of five lipoxygenase activating protein (FLAP) by MK‐886 decreases atherosclerosis in apoE/LDLR‐double knockout mice , 2006, European journal of clinical investigation.

[28]  Kathleen Barnes,et al.  Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. , 2006, American journal of respiratory and critical care medicine.

[29]  G. Hansson,et al.  Leukotriene receptors in atherosclerosis , 2006, Annals of medicine.

[30]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[31]  E E Schadt,et al.  Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits , 2005, Nature Genetics.

[32]  Jesse D. Roberts,et al.  Inhibition of Atherogenesis in BLT1-Deficient Mice Reveals a Role for LTB4 and BLT1 in Smooth Muscle Cell Recruitment , 2005, Circulation.

[33]  U. Thorsteinsdóttir,et al.  Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. , 2005, American journal of human genetics.

[34]  A. Lusis,et al.  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. , 2004, The New England journal of medicine.

[35]  J. Gulcher,et al.  The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke , 2004, Nature Genetics.

[36]  J. Suttles,et al.  Role of Leukotriene B4 Receptors in the Development of Atherosclerosis: Potential Mechanisms , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[37]  M. Mehrabian,et al.  5-Lipoxygenase and atherosclerosis , 2003, Current opinion in lipidology.

[38]  T. Cohnert,et al.  Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Lusis,et al.  Identification of 5-Lipoxygenase as a Major Gene Contributing to Atherosclerosis Susceptibility in Mice , 2002, Circulation research.

[40]  H. Showell,et al.  Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[41]  M. Sanak,et al.  Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. , 2000, American journal of respiratory cell and molecular biology.

[42]  K. Livak,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay. , 1999, Genetic analysis : biomolecular engineering.

[43]  B. Samuelsson.  Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. , 1983, Science.

[44]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[45]  Stanley L Hazen,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[46]  Eric E. Schadt,et al.  Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits , 2005 .

[47]  K. Livak.  SNP genotyping by the 5'-nuclease reaction. , 2003, Methods in molecular biology.

[48]  K. Livak.  SNP Genotyping by the ′’-Nuclease Reaction , 2003 .

[49]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .